Valuation Assessment of Oscar Health Inc (OSCR)On October 05, 2026, Oscar Health Inc (OSCR) shares rose 4.8% to $32.42, marking a significant year-to-date incre

Oscar Health's premium valuation reflects surging membership, improving profitability, a scalable tech platform and growth targets through 2027.

WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on October 5th, 2026.

Oscar Health, Inc. (OSCR) reached $29.9 at the closing of the latest trading day, reflecting a -3.05% change compared to its last close.

The healthcare sector has performed fairly well so far in 2026 due to several factors: GLP-1 medications continue to drive new business and interest, while groundbreaking AI applications help enhance and accelerate the drug discovery process. On top of that, potential mergers and acquisitions activity, as big pharmaceutical companies face a major patent cliff, could provide opportunities for new firms to stand out.

Oscar Health is rated a buy, targeting a $45-$49 fair value, driven by scalable growth and margin expansion in the ACA market. OSCR grew membership 60% while the overall ACA market contracted 13%, achieving a 30% market share and improving the medical loss ratio to 81.5%. Management guides for 2029 revenue CAGR above 20%, a 5-7% operating margin, and $4+ EPS, with the Lucie marketplace as a key incremental driver.

WOOF, FIVE and OSCR made it to the Zacks Rank #1 (Strong Buy) growth stocks list on September 25th, 2026.

Oscar Health's profit rebound faces a test as rising medical spending and a larger member base threaten second-half profitability.

Oscar Health (OSCR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

OSCR, SNDR and TFII made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 23rd, 2026.